-
Ab175993-100μgUlocuplumab (anti-CXCR4) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab (anti-CXCR4) induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab (anti-CXCR4) exhibits antitumor
-
Ab175993-10mgUlocuplumab (anti-CXCR4) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab (anti-CXCR4) induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab (anti-CXCR4) exhibits antitumor
-
Ab175993-1mgUlocuplumab (anti-CXCR4) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab (anti-CXCR4) induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab (anti-CXCR4) exhibits antitumor
-
Ab175993-5mgUlocuplumab (anti-CXCR4) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab (anti-CXCR4) induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab (anti-CXCR4) exhibits antitumor
-
Ab133867-100μlMouse anti Human VAMP8/EDB Antibody, Monoclonal (1414CT354.12.23.93), could be used for WB, IHC and so on.Application· WB: 1/1000-1/2000· IHC: 1/100-1/500Protein FunctionInvolved in the targeting and/or fusion of transport vesicles to their target
-
Ab133867-10μlMouse anti Human VAMP8/EDB Antibody, Monoclonal (1414CT354.12.23.93), could be used for WB, IHC and so on.Application· WB: 1/1000-1/2000· IHC: 1/100-1/500Protein FunctionInvolved in the targeting and/or fusion of transport vesicles to their target
-
Ab133867-1mlMouse anti Human VAMP8/EDB Antibody, Monoclonal (1414CT354.12.23.93), could be used for WB, IHC and so on.Application· WB: 1/1000-1/2000· IHC: 1/100-1/500Protein FunctionInvolved in the targeting and/or fusion of transport vesicles to their target
-
Ab133867-50μlMouse anti Human VAMP8/EDB Antibody, Monoclonal (1414CT354.12.23.93), could be used for WB, IHC and so on.Application· WB: 1/1000-1/2000· IHC: 1/100-1/500Protein FunctionInvolved in the targeting and/or fusion of transport vesicles to their target
-
Ab176175-100μgVandortuzumab (anti-STEAP1) is a recombinant monoclonal antibody that specifically targets STEAP1. It has potential for the treatment of prostate cancer.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab176175-10mgVandortuzumab (anti-STEAP1) is a recombinant monoclonal antibody that specifically targets STEAP1. It has potential for the treatment of prostate cancer.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab176175-1mgVandortuzumab (anti-STEAP1) is a recombinant monoclonal antibody that specifically targets STEAP1. It has potential for the treatment of prostate cancer.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab176175-5mgVandortuzumab (anti-STEAP1) is a recombinant monoclonal antibody that specifically targets STEAP1. It has potential for the treatment of prostate cancer.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.